Andrea Giacomelli
Overview
Explore the profile of Andrea Giacomelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
181
Citations
2376
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gagliardini R, Giacomelli A, Mussini C, Cole S, Edwards J, Pinnetti C, et al.
Int J Infect Dis
. 2025 Mar;
:107883.
PMID: 40089053
Background: No randomized comparisons exist between dolutegravir (DTG) and boosted-darunavir (DRV/b) for people initiating treatment with advanced HIV. Methods: ART-naïve people with HIV (PWH) with CD4 <200 cells/mm or AIDS...
2.
Testa J, Cattaneo D, Giacomelli A, Lai A, Ridolfo A, Gori A, et al.
AIDS
. 2025 Mar;
39(5):625-626.
PMID: 40080172
No abstract available.
3.
Galli M, Giacomelli A, Lai A, Zehender G
Infez Med
. 2025 Mar;
33(1):76-89.
PMID: 40071262
The first highly pathogenic H5N1 emerged in 1959 on a chicken farm in Scotland. The ancestor of the strains presently circulating was isolated in 1996 from a domestic goose in...
4.
Rizzo A, De Vito A, Lucis R, Mileto D, Giacomelli A
Am J Infect Control
. 2025 Feb;
53(3):411-412.
PMID: 40010874
No abstract available.
5.
Vergori A, Gianotti N, Tavelli A, Tincati C, Giacomelli A, Matteini E, et al.
Viruses
. 2025 Jan;
16(12.
PMID: 39772133
: This study examined the impact of the COVID-19 lockdown on antiretroviral therapy (ART) prescriptions among persons living with HIV (PWH) in Italy. : Data from the ICONA cohort included...
6.
Clemente T, Diotallevi S, Minisci D, Di Biagio A, Lolatto R, Attala L, et al.
J Antimicrob Chemother
. 2024 Dec;
80(3):731-737.
PMID: 39727173
Background: Major adverse cardiovascular events (MACEs) may contribute to the high morbidity in people with four-class drug-resistant HIV (4DR-PWH). Objectives: To explore the probability of MACEs in 4DR-PWH compared with...
7.
Carrozzo G, Caloni B, Giacomelli A, Oreni L, Caronni S, Lazzarin S, et al.
Int J Cardiol
. 2024 Nov;
420:132742.
PMID: 39566586
Background: People with HIV (PWH) are at increased risk of atherosclerotic cardiovascular disease (ASCVD). Lowering low-density lipoprotein cholesterol (LDL-C) is central of cardiovascular disease prevention. The aim of this study...
8.
Ciccullo A, Baldin G, Cervo A, Moschese D, Lagi F, Cossu M, et al.
J Antimicrob Chemother
. 2024 Oct;
80(1):175-177.
PMID: 39478330
Objectives: We compared the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) and dolutegravir plus lamivudine (DTG + 3TC) in our cohort of treatment-naive people with HIV (PWH). Methods: In...
9.
Rizzo A, Mendola M, Salari F, Lombardi A, Longo M, Giacomelli A, et al.
J Med Virol
. 2024 Oct;
96(10):e70015.
PMID: 39411895
No abstract available.
10.
Canuti M, Fassio F, Genovese C, Giacomelli A, Ridolfo A, Asperges E, et al.
Infect Dis Ther
. 2024 Oct;
13(11):2471-2474.
PMID: 39352650
No abstract available.